Celsion Corporation (CLSN)

[dia76ca]

Todays GEN-1 ovarian cancer trial results are very encouraging. Dr. Borys summed them up as follows..."The clinical data at the three highest doses of GEN-1 showed an 82% R0 resection rate, compared with a 50% R0 resection rate for the NACT only control arm of the OVATION 2 Study. Historical levels of R0 resections after interval debulking surgery range from 40% to 60%."